AMD

The study illustrates efficacy of AVT06 as compared with aflibercept (Eylea) for neovascular age-related macular degeneration

Real-world data from using faricimab to treat neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME)

The study results will help to identify dosing levels for future clinical trials

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD

The company received marketing authorisation approval in the EU earlier this year

The endorsement follows FDA approval in the United States this summer

Peter K. Kaiser, MD, provides an overview of innovative therapies in development for patients with dry age-related macular degeneration.

Data indicated switching to SB15 from AFL maintained comparable clinical efficacy and safety, confirming biosimilarity between these agents

Case 1 highlights the potential for this treatment for patients with dry AMD with noted letter gains

The 23rd annual EURETINA Congress took place in Amsterdam, the Netherlands. We spoke with Arshad M. Khanani, MD, MA, FASRS, who provided an overview of his presentation, "Emerging therapies for exudative AMD"

Robyn Guymer, MBBS, PhD, Deputy Director, Centre for Eye Research Australia, and Professor of Surgery (Ophthalmology), University of Melbourne, Australia, discussed the study findings at the 23rd annual EURETINA Congress in Amsterdam, the Netherlands

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022

According to the company, it is working with the FDA to address the agency’s issues.

The geographic atrophy treatment was approved by the FDA in the US earlier this month.

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

IZERVAY is expected to be available in the United States within 2 to 4 weeks.

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended.

Faricimab is currently approved in more than 70 countries to treat nAMD and DME, with more than 1 million doses distributed globally, and Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists annual meeting in Seattle.

The Biocon Biologics, Ltd product moves on to review by the European Commission, with an expected decision in late September 2023.

Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.

Dr Varun Chaudhary discusses the impact of personalized treat-and-extend-based dosing on visual and anatomic outcomes of faricimab in the TENAYA and LUCERNE clinical trials in neovascular AMD.

While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.

The company announced the Complete Response Letter from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

Dr Christiana Dinah discusses her SOE presentation, "Geographic Atrophy: A Mixed Method Study."

RGC replacement represents a more formidable challenge.